TORAY INDUSTRIES, INC.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 1926-04-16
- Employees
- 48.1K
- Market Cap
- -
- Website
- http://www.toray.co.jp
Clinical Trials
36
Active:14
Completed:15
Trial Phases
3 Phases
Phase 1:15
Phase 2:8
Not Applicable:5
Drug Approvals
6
NMPA:6
Drug Approvals
Nalfurafine Hydrochloride Orally Disintegrating Tablets
- Product Name
- 盐酸纳呋拉啡口崩片
- Approval Number
- 国药准字HJ20230091
- Approval Date
- Sep 13, 2023
NMPA
Beraprost Sodium Sustained-release Tablets
- Product Name
- 贝前列素钠缓释片
- Approval Number
- 国药准字HJ20220067
- Approval Date
- Jul 26, 2022
NMPA
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
Phase 1
15 (53.6%)Phase 2
8 (28.6%)Not Applicable
5 (17.9%)A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Phase 2
Recruiting
- Conditions
- Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaGastric Cancer
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Toray Industries, Inc
- Target Recruit Count
- 146
- Registration Number
- NCT06038578
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸City of Hope at Orange County Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸University of California, Los Angeles, Santa Monica, California, United States
A Study of TRK-950 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Toray Industries, Inc
- Target Recruit Count
- 13
- Registration Number
- NCT05423262
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome)
Not Applicable
Recruiting
- Conditions
- Acute Respiratory Distress Syndrome
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Toray Industries, Inc
- Target Recruit Count
- 45
- Registration Number
- NCT04804943
- Locations
- 🇯🇵
Showa University Hospital, Tokyo, Japan
A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study)
Phase 2
Withdrawn
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- Drug: TRK-750/PlaceboDrug: Placebo/TRK-750
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Toray Industries, Inc
- Registration Number
- NCT04282590
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Solid TumorColorectal CancerGastric CancerRenal Cell CarcinomaMelanomaEpithelial Ovarian CancerPrimary Peritoneal CancerFallopian Tube CancerCholangiocarcinomaBladder Cancer
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Toray Industries, Inc
- Target Recruit Count
- 138
- Registration Number
- NCT03872947
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸AOA-HOPE, Tucson, Arizona, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found